Curis, Inc. (NASDAQ:CRIS) Q1 2024 Earnings Conference Call May 7, 2024 8:30 AM ET

Company Participants

Diantha Duvall - CFO
Jim Dentzer - President & CEO
Robert Martell - Chief Scientific Officer

Conference Call Participants

Soumit Roy - JonesTrading
Li Watsek - Cantor Fitzgerald
Yale Jen - Laidlaw & Company
Billal Jahangiri - Truist Securities
Sean McCutcheon - Raymond James

Operator

Good morning, ladies and gentlemen, and welcome to the Curis First Quarter 2024 Business Update. At this time all lines are in listen-only mode. Following the presentation we will conduct a question-and-answer session [Operator Instructions].

This call is being recorded on Tuesday, May 7, 2024. I would now like to turn the conference over to Diantha Duvall. Please go ahead.

Diantha Duvall

Thank you, and welcome to Curis' First Quarter 2024 Business Update Call. Before we begin, I would like to encourage everyone to go to the Investors section of our website at www.curis.com to find our first quarter 2024 business update press release and related financial tables.

I would also like to remind everyone that during the call, we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties and actual results may differ materially. For additional details, please see our SEC filings.

Joining me today on today's call are Jim Dentzer, President and Chief Executive Officer; Bob Martell, Chief Scientific Officer; and Jonathan Zung, Chief Development Officer. We will also be available for a question-and-answer period at the end of the call.

I'd now like to turn the call over to Jim.

Jim Dentzer

Thank you, Diantha. Good morning, everyone, and welcome to Curis' Q1 business update call. This quarter, we made significant progress in advancing emavusertib in our three key areas of focus. First, as a monotherapy in patients with relapsed refractory AML and with a FLT3 or splicing factor mutation in our TakeAim Leukemia study. Second, as a doublet therapy for patients with relapsed/refractory primary CNS lymphoma, combining emavusertib with ibrutinib in our TakeAim lymphoma study. And third, as a triplet therapy in frontline AML for all comers regardless of mutation status, that combines emavusertib with azacitidine and venetoclax.

Next Tuesday, in connection with the EHA conferences publication of accepted abstracts, we expect to provide a top line update of clinical data from our TakeAim leukemia study. Previously, we had disclosed data for five patients. Three patients with a FLT3 mutation and three patients with a splicing factor mutation, including one patient with both a FLT3 and a splicing factor mutation who was included in both populations. Our update next week will report data for 25 new patients, bringing the total to 30 relapsed/refractory AML patients treated with emavusertib as a monotherapy.